Definition of “Positional Isomer” as It Pertains to the Control of Schedule I Controlled Substances, 67850-67852 [E7-23413]
Download as PDF
67850
Federal Register / Vol. 72, No. 231 / Monday, December 3, 2007 / Rules and Regulations
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1300
[Docket No. DEA–260F]
RIN 1117–AA94
Definition of ‘‘Positional Isomer’’ as It
Pertains to the Control of Schedule I
Controlled Substances
Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Final Rule.
AGENCY:
On May 25, 2006, DEA
published a Notice of Proposed
Rulemaking which proposed the
addition of a specific definition for the
term ‘‘positional isomer’’ to allow for
the systematic determination of which
isomers of schedule I substances would
be considered to be ‘‘positional,’’ and
therefore, subject to schedule I control.
This rulemaking finalizes that
definition.
The Controlled Substances Act (CSA)
and its implementing regulations
specify which hallucinogenic
substances are considered schedule I
controlled substances. The CSA states
that all salts, isomers, and salts of
isomers of these substances are also
schedule I controlled substances. In
non-technical terms, an isomer of a
substance is a different compound, but
a compound which has the same
number and kind of atoms. The terms
‘‘optical isomer’’ and ‘‘geometric
isomer’’ are specific scientific terms and
it is easy to determine whether one
substance is an optical or geometric
isomer of another. The term ‘‘positional
isomer,’’ however, is subject to scientific
interpretation.
The addition of a definition for the
term ‘‘positional isomer’’ will assist
legitimate research[ers] and industry in
determining the control status of
materials that are ‘‘positional isomers’’
of schedule I hallucinogens. While the
DEA will remain the authority for
ultimately determining the control
status of a given material, providing a
specific definition for ‘‘positional
isomer’’ will ensure consistent criteria
are utilized in making these
determinations.
This rule does not change existing
laws, regulations, policies, processes,
and procedures regarding the
determination of control status for
schedule I hallucinogenic substances.
This rule merely makes available to the
public the longstanding definition of
‘‘positional isomer’’ which DEA has
yshivers on PROD1PC62 with RULES
SUMMARY:
VerDate Aug<31>2005
14:39 Nov 30, 2007
Jkt 214001
used when making these scheduling
determinations.
This rule is relevant only to
specialized forensic or research
chemists. Most of these individuals are
existing DEA registrants who are
authorized by the DEA to handle
schedule I hallucinogenic substances.
DATES: Effective January 2, 2008.
FOR FURTHER INFORMATION CONTACT:
Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537 at (202) 307–
7183.
SUPPLEMENTARY INFORMATION:
Background
On May 25, 2006, DEA published a
Notice of Proposed Rulemaking (NPRM)
[71 FR 30097] which proposed the
addition of a specific definition for the
term ‘‘positional isomer.’’ As DEA
discussed in the NPRM, in many
instances, the control of a substance
under the CSA often includes the
specific substance listed under the CSA,
as well as the substance’s salts, isomers,
and/or salts of isomers. In most
instances, the term isomer includes only
optical isomers. In other instances,
however, the term isomer includes
positional and/or geometric isomers.
As DEA discussed in its NPRM, in
non-technical terms, isomers are
different compounds that have the same
molecular formula (the same number
and types of atoms). The terms ‘‘optical
isomer’’ and ‘‘geometric isomer’’ are
specifically defined and well
understood scientific terms, and it is
easy to determine whether one
substance is an optical or geometric
isomer of another. The term ‘‘positional
isomer,’’ however, is not universally
defined, and, therefore, is subject to
scientific interpretation. In order to
ensure that consistent criteria are
utilized in determining whether one
substance is considered a ‘‘positional
isomer’’ of another, the DEA is
establishing a specific definition for
‘‘positional isomer.’’ This definition will
be added to 21 CFR 1300.01(b)(21).
Existing CSA and CFR References to
‘‘Positional Isomers’’
The CSA and its implementing
regulations (21 CFR 1308.11(d)) specify
which hallucinogenic substances are
considered schedule I controlled
substances. Under the CSA and its
implementing regulations, there are
only three references to the term
‘‘positional isomer’’:
(1) Pursuant to 21 U.S.C. 802(14), ‘‘the
term ‘isomer’ means the optical isomer,
PO 00000
Frm 00020
Fmt 4700
Sfmt 4700
except as used in schedule I(c) and
schedule II(a)(4). As used in schedule
I(c), the term ‘isomer’ means any
optical, positional, or geometric isomer.
As used in schedule II(a)(4), the term
‘isomer’ means any optical or geometric
isomer.’’
(2) Under 21 CFR 1300.01(b)(21),
‘‘The term ‘isomer’ means the optical
isomer, except as used in §§ 1308.11(d)
and 1308.12(b)(4) of this chapter. As
used in § 1308.11(d) of this chapter, the
term ‘isomer’ means the optical,
positional, or geometric isomer. As used
in § 1308.12(b)(4) of this chapter, the
term ‘isomer’ means the optical or
geometric isomer.’’
(3) 21 CFR 1308.11(d) states,
‘‘Hallucinogenic substances. Unless
specifically excepted or unless listed in
another schedule, any material,
compound, mixture, or preparation,
which contains any quantity of the
following hallucinogenic substances, or
which contains any of its salts, isomers,
and salts of isomers whenever the
existence of such salts, isomers, and
salts of isomers is possible within the
specific chemical designation (for
purposes of this paragraph only, the
term ’isomer’ includes the optical,
positional and geometric isomers).’’
Why Definition Is Needed
As DEA discussed in the NPRM, the
CSA (21 U.S.C. 802(14) and 21 U.S.C.
812(c)(I)(c)) and its implementing
regulations (21 CFR 1308.11(d)) specify
which hallucinogenic substances are
considered schedule I controlled
substances. The CSA further states that
all salts, isomers, and salts of isomers of
these substances are also schedule I
controlled substances.
Under the definition of ‘‘isomer’’
found in 21 CFR 1300.01(b)(21), ‘‘The
term ‘isomer’ means the optical isomer,
except as used in §§ 1308.11(d) and
1308.12(b)(4) of this chapter. As used in
§ 1308.11(d) of this chapter, the term
‘isomer’ means the optical, positional,
or geometric isomer. As used in
§ 1308.12(b)(4) of this chapter, the term
‘isomer’ means the optical or geometric
isomer.’’
Therefore, according to this definition
as it specifically applies to
hallucinogens, the term ‘‘isomer’’
includes all optical, positional, or
geometric isomers. As such, all salts,
isomers (including optical, positional,
or geometric isomers), and salts of
isomers (including optical, positional,
or geometric isomers) of the
hallucinogenic substances listed in 21
U.S.C. 812(c)(I)(c) and 21 CFR
1308.11(d) are considered schedule I
controlled substances.
E:\FR\FM\03DER1.SGM
03DER1
Federal Register / Vol. 72, No. 231 / Monday, December 3, 2007 / Rules and Regulations
Because the determination as to
whether a substance is considered a
‘‘positional isomer’’ can be subject to
scientific interpretation, the DEA
believes it is necessary to specifically
define the term ‘‘positional isomer’’.
This definition will only pertain to
those substances that are ‘‘positional
isomers’’ of schedule I controlled
substances pursuant to 21 U.S.C.
812(c)(I)(c) and 21 CFR 1308.11(d).
As DEA noted in the NPRM, DEA is
not establishing definitions for either
optical or geometric isomers. The DEA
believes that these terms are highly
specific and are not subject to differing
scientific interpretation.
yshivers on PROD1PC62 with RULES
Comments
The definition of ‘‘positional isomer’’
will be used in the determination of the
control status of substances as schedule
I controlled substances pursuant to 21
CFR 1308.11(d). This definition is
highly technical in nature and the DEA
has sought to provide specific criteria
for determination as to whether a
substance is a ‘‘positional isomer’’ of
schedule I hallucinogens. In writing the
definition contained in this rulemaking,
DEA consulted a wide variety of
reference sources including, but not
limited to, Chemical Abstracts, the
IUPAC Compendium of Chemical
Terminology, World Health
Organization (WHO) documents, and
various encyclopedias and chemistry
textbooks.
The NPRM sought input from all
interested parties regarding the
proposed definition of ‘‘positional
isomer.’’ DEA received one comment in
response to the proposed definition.
That comment did not raise any specific
objections to the definition, but
expressed the opinion that instead of
DEA adding this definition, this duty
should be the responsibility of Congress
and the definition added via legislation.
DEA disagrees. 21 U.S.C. 821
authorizes the Attorney General to
‘‘promulgate rules and regulations and
to charge reasonable fees relating to the
registration and control of the
manufacture, distribution, and
dispensing of controlled substances.’’
Expanding on this authority, 21 U.S.C.
871(b) further provides that the
Attorney General ‘‘may promulgate and
enforce any rules, regulations, and
procedures which he may deem
necessary and appropriate for the
efficient execution of his functions.’’
The authority has been delegated by the
Attorney General to the Administrator
of DEA pursuant to 28 CFR 0.100, and
redelegated to the Deputy Administrator
pursuant to 28 CFR 0.104.
VerDate Aug<31>2005
14:39 Nov 30, 2007
Jkt 214001
It is, therefore, well within the Deputy
Administrator’s purview to issue a
notice of proposed rulemaking to define
a term relating to the control of certain
schedule I controlled substances. By
inviting comment to the proposed
definition, DEA ensured that potentially
affected persons, such as researchers,
were given the opportunity to review
the definition and submit comments or
changes. No other comments were
received by DEA. Therefore, this
rulemaking finalizes the definition
exactly as it was proposed in the NPRM.
Criteria That Will Apply to Positional
Isomers
Pursuant to 21 U.S.C. 802(14), 21
U.S.C. 812(c)(I)(c), and 21 CFR
1308.11(d), positional isomers of
schedule I hallucinogens are any and all
substances which:
(1) Are not already controlled in a
different schedule I category, or are
listed in another schedule, or are
specifically exempted from control by
law; and
(2) Have the same molecular formula
and core structure as a schedule I
hallucinogen; and
(3) Have the same functional group(s)
and/or substituent(s) as those found in
the respective schedule I hallucinogen,
attached at any position(s) on the core
structure, but in such manner that no
new chemical functionalities are created
and no existing chemical functionalities
are destroyed relative to the respective
schedule I hallucinogen; except that
(4) Rearrangements of alkyl moieties
within or between functional group(s) or
substituent(s), or divisions or
combinations of alkyl moieties, that do
not create new chemical functionalities
or destroy existing chemical
functionalities, would be within the
definition of positional isomer (and
therefore be controlled).
As clarification, note that the ‘‘core
structure’’ is the parent molecule that is
the common basis for the class; for
example, tryptamine, phenethylamine,
or ergoline. The following are examples
of rearrangements resulting in creation
and/or destruction of chemical
functionalities. These rearrangements
result in compounds which are not
positional isomers: ethoxy to alphahydroxyethyl, hydroxy and methyl to
methoxy, or the repositioning of a
phenolic or alcoholic hydroxy group to
create a hydroxyamine. Examples of
rearrangements resulting in compounds
that would be positional isomers
include, but are not limited to: tert-butyl
to sec-butyl, methoxy and ethyl to
isopropoxy, N,N-diethyl to N-methyl-Npropyl, or alpha-methylamino to Nmethylamino.
PO 00000
Frm 00021
Fmt 4700
Sfmt 4700
67851
Impact of Rule Limited to Specialized
Forensic or Research Chemists
As DEA discussed in the NPRM, the
addition of a definition for the term
‘‘positional isomer’’ as it applies to 21
CFR 1308.11(d) will assist legitimate
research[ers] and industry in
determining the control status of
substances that are isomers of schedule
I hallucinogens. While the DEA will
remain the authority on ultimately
determining the control status of a given
substance, providing a specific
definition for ‘‘positional isomer’’ will
greatly reduce any potential confusion
or inconsistencies in making these
determinations.
This definition will enable
researchers and industry to determine
definitively whether a substance is a
‘‘positional isomer’’ of a schedule I
hallucinogen. As such, they will be able
to know the control status of a particular
substance when considering new
research.
This rule is relevant only to
specialized forensic or research
chemists. Most of these individuals are
existing DEA registrants who are
authorized by the DEA to handle
schedule I hallucinogenic substances.
Specific Changes and Definition
As currently defined in 21 CFR
1300.01(b)(21), the term ‘‘isomer’’
means the optical isomer, except as
used in § 1308.11(d) and § 1308.12(b)(4)
of this chapter. As used in § 1308.11(d)
of this chapter, the term ‘‘isomer’’
means any optical, positional, or
geometric isomer. As used in
§ 1308.12(b)(4) of this chapter, the term
‘‘isomer’’ means any optical or
geometric isomer.
Pursuant to this Final Rule, 21 CFR
1300.01(b)(21) is revised to include a
specific definition for the term
‘‘positional isomer’’. The modification
specifies that, as used in § 1308.11(d),
the term ‘‘positional isomer’’ means any
substance possessing the same
molecular formula and core structure
and having the same functional group(s)
and/or substituent(s) as those found in
the respective schedule I hallucinogen,
attached at any position(s) on the core
structure, but in such manner that no
new chemical functionalities are created
and no existing chemical functionalities
are destroyed relative to the respective
schedule I hallucinogen.
Rearrangements of alkyl moieties within
or between functional group(s) or
substituent(s), or divisions or
combinations of alkyl moieties that do
not create new chemical functionalities
or destroy existing chemical
functionalities, would be within the
E:\FR\FM\03DER1.SGM
03DER1
67852
Federal Register / Vol. 72, No. 231 / Monday, December 3, 2007 / Rules and Regulations
definition of positional isomer. For
purposes of this definition, the ‘‘core
structure’’ is the parent molecule that is
the common basis for the class. Some
examples would include tryptamine,
phenethylamine, or ergoline. Examples
of non-permissible rearrangements
resulting in creation and/or destruction
of chemical functionalities (that
therefore would not be considered
positional isomers) include, but are not
limited to: ethoxy to alphahydroxyethyl, hydroxy and methyl to
methoxy, or the repositioning of a
phenolic or alcoholic hydroxy group to
create a hydroxyamine. Examples of
permissible rearrangements (that are
within the definition of positional
isomers) include: tert-butyl to sec-butyl,
methoxy and ethyl to isopropoxy, N,Ndiethyl to N-methyl-N-propyl, or alphamethylamino to N-methylamino.
Scientific/Technical Nature of
Definition
As DEA discussed in its NPRM, DEA
understands that the definition is highly
technical and laden with scientific
terms. However, the DEA believes that
such a highly technical definition is
necessary to ensure that consistent
criteria are utilized in determining
whether one substance is a ‘‘positional
isomer’’ of another.
Regulatory Certifications
yshivers on PROD1PC62 with RULES
Regulatory Flexibility Act
The Deputy Administrator hereby
certifies that this rulemaking has been
drafted in accordance with the
Regulatory Flexibility Act (5 U.S.C.
605(b)), has reviewed this regulation,
and by approving it certifies that this
regulation will not have a significant
economic impact on a substantial
number of small entities. The inclusion
of the definition of positional isomer set
forth herein is unlikely to subject any
new substances to CSA control. Also,
this rule does not require the obtaining
of new DEA registrations. Most persons
affected by this rule are already DEA
registrants (or would have to become
registrants even absent this rule in order
to handle schedule I hallucinogens).
Further, this rule does not impose any
additional regulatory burden on the
regulated community. The change
simply will ensure that consistent
criteria are utilized in making
scheduling determinations.
Executive Order 12866
The Deputy Administrator further
certifies that this rulemaking has been
drafted in accordance with the
principles in Executive Order 12866
§ 1(b). It has been determined that this
is a significant regulatory action.
VerDate Aug<31>2005
14:39 Nov 30, 2007
Jkt 214001
Therefore, this action has been reviewed
by the Office of Management and
Budget.
Executive Order 12988
This regulation meets the applicable
standards set forth in §§ 3(a) and 3(b)(2)
of Executive Order 12988 Civil Justice
Reform.
Executive Order 13132
This rulemaking does not preempt or
modify any provision of state law; nor
does it impose enforcement
responsibilities on any state; nor does it
diminish the power of any state to
enforce its own laws. Accordingly, this
rulemaking does not have federalism
implications warranting the application
of Executive Order 13132.
Unfunded Mandates Reform Act of
1995
This rule will not result in the
expenditure by State, local, and tribal
governments, in the aggregate, or by the
private sector, of $120,000,000 or more
(adjusted for inflation) in any one year,
and will not significantly or uniquely
affect small governments. Therefore, no
actions were deemed necessary under
the provisions of the Unfunded
Mandates Reform Act of 1995.
Congressional Review Act
This rule is not a major rule as
defined by section 804 of the Small
Business Regulatory Enforcement
Fairness Act of 1996 (Congressional
Review Act). This rule will not result in
an annual effect on the economy of
$114,000,000 or more; a major increase
in costs or prices; or significant adverse
effects on competition, employment,
investment, productivity, innovation, or
on the ability of United States-based
companies to compete with foreignbased companies in domestic and
export markets.
List of Subjects in 21 CFR Part 1300
Controlled substances, Definitions,
Drug Traffic Control.
I For the reasons set out above, 21 CFR
part 1300 is amended as follows:
PART 1300—DEFINITIONS [AMENDED]
1. The authority citation for Part 1300
continues to read as follows:
I
Authority: 21 U.S.C. 802, 871(b), 951,
958(f).
2. Section 1300.01 is amended by
revising paragraph (b)(21) to read as
follows:
I
(b) * * *
(21) (i) The term isomer means the
optical isomer, except as used in
§ 1308.11(d) and § 1308.12(b)(4) of this
chapter. As used in § 1308.11(d) of this
chapter, the term ‘‘isomer’’ means any
optical, positional, or geometric isomer.
As used in § 1308.12(b)(4) of this
chapter, the term ‘‘isomer’’ means any
optical or geometric isomer.
(ii) As used in § 1308.11(d) of this
chapter, the term ‘‘positional isomer’’
means any substance possessing the
same molecular formula and core
structure and having the same
functional group(s) and/or substituent(s)
as those found in the respective
schedule I hallucinogen, attached at any
position(s) on the core structure, but in
such manner that no new chemical
functionalities are created and no
existing chemical functionalities are
destroyed relative to the respective
schedule I hallucinogen.
Rearrangements of alkyl moieties within
or between functional group(s) or
substituent(s), or divisions or
combinations of alkyl moieties, that do
not create new chemical functionalities
or destroy existing chemical
functionalities, are allowed i.e., result in
compounds which are positional
isomers. For purposes of this definition,
the ‘‘core structure’’ is the parent
molecule that is the common basis for
the class; for example, tryptamine,
phenethylamine, or ergoline. Examples
of rearrangements resulting in creation
and/or destruction of chemical
functionalities (and therefore resulting
in compounds which are not positional
isomers) include, but are not limited to:
ethoxy to alpha-hydroxyethyl, hydroxy
and methyl to methoxy, or the
repositioning of a phenolic or alcoholic
hydroxy group to create a
hydroxyamine. Examples of
rearrangements resulting in compounds
which would be positional isomers
include: tert-butyl to sec-butyl, methoxy
and ethyl to isopropoxy, N,N-diethyl to
N-methyl-N-propyl, or alphamethylamino to N-methylamino.
*
*
*
*
*
Dated: November 21, 2007.
Michele M. Leonhart,
Deputy Administrator,
[FR Doc. E7–23413 Filed 11–30–07; 8:45 am]
BILLING CODE 4410–09–P
§ 1300.01 Definitions relating to controlled
substances.
*
PO 00000
*
*
Frm 00022
*
Fmt 4700
*
Sfmt 4700
E:\FR\FM\03DER1.SGM
03DER1
Agencies
[Federal Register Volume 72, Number 231 (Monday, December 3, 2007)]
[Rules and Regulations]
[Pages 67850-67852]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-23413]
[[Page 67850]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1300
[Docket No. DEA-260F]
RIN 1117-AA94
Definition of ``Positional Isomer'' as It Pertains to the Control
of Schedule I Controlled Substances
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Final Rule.
-----------------------------------------------------------------------
SUMMARY: On May 25, 2006, DEA published a Notice of Proposed Rulemaking
which proposed the addition of a specific definition for the term
``positional isomer'' to allow for the systematic determination of
which isomers of schedule I substances would be considered to be
``positional,'' and therefore, subject to schedule I control. This
rulemaking finalizes that definition.
The Controlled Substances Act (CSA) and its implementing
regulations specify which hallucinogenic substances are considered
schedule I controlled substances. The CSA states that all salts,
isomers, and salts of isomers of these substances are also schedule I
controlled substances. In non-technical terms, an isomer of a substance
is a different compound, but a compound which has the same number and
kind of atoms. The terms ``optical isomer'' and ``geometric isomer''
are specific scientific terms and it is easy to determine whether one
substance is an optical or geometric isomer of another. The term
``positional isomer,'' however, is subject to scientific
interpretation.
The addition of a definition for the term ``positional isomer''
will assist legitimate research[ers] and industry in determining the
control status of materials that are ``positional isomers'' of schedule
I hallucinogens. While the DEA will remain the authority for ultimately
determining the control status of a given material, providing a
specific definition for ``positional isomer'' will ensure consistent
criteria are utilized in making these determinations.
This rule does not change existing laws, regulations, policies,
processes, and procedures regarding the determination of control status
for schedule I hallucinogenic substances. This rule merely makes
available to the public the longstanding definition of ``positional
isomer'' which DEA has used when making these scheduling
determinations.
This rule is relevant only to specialized forensic or research
chemists. Most of these individuals are existing DEA registrants who
are authorized by the DEA to handle schedule I hallucinogenic
substances.
DATES: Effective January 2, 2008.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, Ph.D., Chief,
Drug and Chemical Evaluation Section, Office of Diversion Control, Drug
Enforcement Administration, Washington, DC 20537 at (202) 307-7183.
SUPPLEMENTARY INFORMATION:
Background
On May 25, 2006, DEA published a Notice of Proposed Rulemaking
(NPRM) [71 FR 30097] which proposed the addition of a specific
definition for the term ``positional isomer.'' As DEA discussed in the
NPRM, in many instances, the control of a substance under the CSA often
includes the specific substance listed under the CSA, as well as the
substance's salts, isomers, and/or salts of isomers. In most instances,
the term isomer includes only optical isomers. In other instances,
however, the term isomer includes positional and/or geometric isomers.
As DEA discussed in its NPRM, in non-technical terms, isomers are
different compounds that have the same molecular formula (the same
number and types of atoms). The terms ``optical isomer'' and
``geometric isomer'' are specifically defined and well understood
scientific terms, and it is easy to determine whether one substance is
an optical or geometric isomer of another. The term ``positional
isomer,'' however, is not universally defined, and, therefore, is
subject to scientific interpretation. In order to ensure that
consistent criteria are utilized in determining whether one substance
is considered a ``positional isomer'' of another, the DEA is
establishing a specific definition for ``positional isomer.'' This
definition will be added to 21 CFR 1300.01(b)(21).
Existing CSA and CFR References to ``Positional Isomers''
The CSA and its implementing regulations (21 CFR 1308.11(d))
specify which hallucinogenic substances are considered schedule I
controlled substances. Under the CSA and its implementing regulations,
there are only three references to the term ``positional isomer'':
(1) Pursuant to 21 U.S.C. 802(14), ``the term `isomer' means the
optical isomer, except as used in schedule I(c) and schedule II(a)(4).
As used in schedule I(c), the term `isomer' means any optical,
positional, or geometric isomer. As used in schedule II(a)(4), the term
`isomer' means any optical or geometric isomer.''
(2) Under 21 CFR 1300.01(b)(21), ``The term `isomer' means the
optical isomer, except as used in Sec. Sec. 1308.11(d) and
1308.12(b)(4) of this chapter. As used in Sec. 1308.11(d) of this
chapter, the term `isomer' means the optical, positional, or geometric
isomer. As used in Sec. 1308.12(b)(4) of this chapter, the term
`isomer' means the optical or geometric isomer.''
(3) 21 CFR 1308.11(d) states, ``Hallucinogenic substances. Unless
specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation, which contains any
quantity of the following hallucinogenic substances, or which contains
any of its salts, isomers, and salts of isomers whenever the existence
of such salts, isomers, and salts of isomers is possible within the
specific chemical designation (for purposes of this paragraph only, the
term 'isomer' includes the optical, positional and geometric
isomers).''
Why Definition Is Needed
As DEA discussed in the NPRM, the CSA (21 U.S.C. 802(14) and 21
U.S.C. 812(c)(I)(c)) and its implementing regulations (21 CFR
1308.11(d)) specify which hallucinogenic substances are considered
schedule I controlled substances. The CSA further states that all
salts, isomers, and salts of isomers of these substances are also
schedule I controlled substances.
Under the definition of ``isomer'' found in 21 CFR 1300.01(b)(21),
``The term `isomer' means the optical isomer, except as used in
Sec. Sec. 1308.11(d) and 1308.12(b)(4) of this chapter. As used in
Sec. 1308.11(d) of this chapter, the term `isomer' means the optical,
positional, or geometric isomer. As used in Sec. 1308.12(b)(4) of this
chapter, the term `isomer' means the optical or geometric isomer.''
Therefore, according to this definition as it specifically applies
to hallucinogens, the term ``isomer'' includes all optical, positional,
or geometric isomers. As such, all salts, isomers (including optical,
positional, or geometric isomers), and salts of isomers (including
optical, positional, or geometric isomers) of the hallucinogenic
substances listed in 21 U.S.C. 812(c)(I)(c) and 21 CFR 1308.11(d) are
considered schedule I controlled substances.
[[Page 67851]]
Because the determination as to whether a substance is considered a
``positional isomer'' can be subject to scientific interpretation, the
DEA believes it is necessary to specifically define the term
``positional isomer''. This definition will only pertain to those
substances that are ``positional isomers'' of schedule I controlled
substances pursuant to 21 U.S.C. 812(c)(I)(c) and 21 CFR 1308.11(d).
As DEA noted in the NPRM, DEA is not establishing definitions for
either optical or geometric isomers. The DEA believes that these terms
are highly specific and are not subject to differing scientific
interpretation.
Comments
The definition of ``positional isomer'' will be used in the
determination of the control status of substances as schedule I
controlled substances pursuant to 21 CFR 1308.11(d). This definition is
highly technical in nature and the DEA has sought to provide specific
criteria for determination as to whether a substance is a ``positional
isomer'' of schedule I hallucinogens. In writing the definition
contained in this rulemaking, DEA consulted a wide variety of reference
sources including, but not limited to, Chemical Abstracts, the IUPAC
Compendium of Chemical Terminology, World Health Organization (WHO)
documents, and various encyclopedias and chemistry textbooks.
The NPRM sought input from all interested parties regarding the
proposed definition of ``positional isomer.'' DEA received one comment
in response to the proposed definition. That comment did not raise any
specific objections to the definition, but expressed the opinion that
instead of DEA adding this definition, this duty should be the
responsibility of Congress and the definition added via legislation.
DEA disagrees. 21 U.S.C. 821 authorizes the Attorney General to
``promulgate rules and regulations and to charge reasonable fees
relating to the registration and control of the manufacture,
distribution, and dispensing of controlled substances.'' Expanding on
this authority, 21 U.S.C. 871(b) further provides that the Attorney
General ``may promulgate and enforce any rules, regulations, and
procedures which he may deem necessary and appropriate for the
efficient execution of his functions.'' The authority has been
delegated by the Attorney General to the Administrator of DEA pursuant
to 28 CFR 0.100, and redelegated to the Deputy Administrator pursuant
to 28 CFR 0.104.
It is, therefore, well within the Deputy Administrator's purview to
issue a notice of proposed rulemaking to define a term relating to the
control of certain schedule I controlled substances. By inviting
comment to the proposed definition, DEA ensured that potentially
affected persons, such as researchers, were given the opportunity to
review the definition and submit comments or changes. No other comments
were received by DEA. Therefore, this rulemaking finalizes the
definition exactly as it was proposed in the NPRM.
Criteria That Will Apply to Positional Isomers
Pursuant to 21 U.S.C. 802(14), 21 U.S.C. 812(c)(I)(c), and 21 CFR
1308.11(d), positional isomers of schedule I hallucinogens are any and
all substances which:
(1) Are not already controlled in a different schedule I category,
or are listed in another schedule, or are specifically exempted from
control by law; and
(2) Have the same molecular formula and core structure as a
schedule I hallucinogen; and
(3) Have the same functional group(s) and/or substituent(s) as
those found in the respective schedule I hallucinogen, attached at any
position(s) on the core structure, but in such manner that no new
chemical functionalities are created and no existing chemical
functionalities are destroyed relative to the respective schedule I
hallucinogen; except that
(4) Rearrangements of alkyl moieties within or between functional
group(s) or substituent(s), or divisions or combinations of alkyl
moieties, that do not create new chemical functionalities or destroy
existing chemical functionalities, would be within the definition of
positional isomer (and therefore be controlled).
As clarification, note that the ``core structure'' is the parent
molecule that is the common basis for the class; for example,
tryptamine, phenethylamine, or ergoline. The following are examples of
rearrangements resulting in creation and/or destruction of chemical
functionalities. These rearrangements result in compounds which are not
positional isomers: ethoxy to alpha-hydroxyethyl, hydroxy and methyl to
methoxy, or the repositioning of a phenolic or alcoholic hydroxy group
to create a hydroxyamine. Examples of rearrangements resulting in
compounds that would be positional isomers include, but are not limited
to: tert-butyl to sec-butyl, methoxy and ethyl to isopropoxy, N,N-
diethyl to N-methyl-N-propyl, or alpha-methylamino to N-methylamino.
Impact of Rule Limited to Specialized Forensic or Research Chemists
As DEA discussed in the NPRM, the addition of a definition for the
term ``positional isomer'' as it applies to 21 CFR 1308.11(d) will
assist legitimate research[ers] and industry in determining the control
status of substances that are isomers of schedule I hallucinogens.
While the DEA will remain the authority on ultimately determining the
control status of a given substance, providing a specific definition
for ``positional isomer'' will greatly reduce any potential confusion
or inconsistencies in making these determinations.
This definition will enable researchers and industry to determine
definitively whether a substance is a ``positional isomer'' of a
schedule I hallucinogen. As such, they will be able to know the control
status of a particular substance when considering new research.
This rule is relevant only to specialized forensic or research
chemists. Most of these individuals are existing DEA registrants who
are authorized by the DEA to handle schedule I hallucinogenic
substances.
Specific Changes and Definition
As currently defined in 21 CFR 1300.01(b)(21), the term ``isomer''
means the optical isomer, except as used in Sec. 1308.11(d) and Sec.
1308.12(b)(4) of this chapter. As used in Sec. 1308.11(d) of this
chapter, the term ``isomer'' means any optical, positional, or
geometric isomer. As used in Sec. 1308.12(b)(4) of this chapter, the
term ``isomer'' means any optical or geometric isomer.
Pursuant to this Final Rule, 21 CFR 1300.01(b)(21) is revised to
include a specific definition for the term ``positional isomer''. The
modification specifies that, as used in Sec. 1308.11(d), the term
``positional isomer'' means any substance possessing the same molecular
formula and core structure and having the same functional group(s) and/
or substituent(s) as those found in the respective schedule I
hallucinogen, attached at any position(s) on the core structure, but in
such manner that no new chemical functionalities are created and no
existing chemical functionalities are destroyed relative to the
respective schedule I hallucinogen. Rearrange ments of alkyl moieties
within or between functional group(s) or substituent(s), or divisions
or combinations of alkyl moieties that do not create new chemical
functionalities or destroy existing chemical functionalities, would be
within the
[[Page 67852]]
definition of positional isomer. For purposes of this definition, the
``core structure'' is the parent molecule that is the common basis for
the class. Some examples would include tryptamine, phenethylamine, or
ergoline. Examples of non-permissible rearrangements resulting in
creation and/or destruction of chemical functionalities (that therefore
would not be considered positional isomers) include, but are not
limited to: ethoxy to alpha-hydroxyethyl, hydroxy and methyl to
methoxy, or the repositioning of a phenolic or alcoholic hydroxy group
to create a hydroxyamine. Examples of permissible rearrangements (that
are within the definition of positional isomers) include: tert-butyl to
sec-butyl, methoxy and ethyl to isopropoxy, N,N-diethyl to N-methyl-N-
propyl, or alpha-methylamino to N-methylamino.
Scientific/Technical Nature of Definition
As DEA discussed in its NPRM, DEA understands that the definition
is highly technical and laden with scientific terms. However, the DEA
believes that such a highly technical definition is necessary to ensure
that consistent criteria are utilized in determining whether one
substance is a ``positional isomer'' of another.
Regulatory Certifications
Regulatory Flexibility Act
The Deputy Administrator hereby certifies that this rulemaking has
been drafted in accordance with the Regulatory Flexibility Act (5
U.S.C. 605(b)), has reviewed this regulation, and by approving it
certifies that this regulation will not have a significant economic
impact on a substantial number of small entities. The inclusion of the
definition of positional isomer set forth herein is unlikely to subject
any new substances to CSA control. Also, this rule does not require the
obtaining of new DEA registrations. Most persons affected by this rule
are already DEA registrants (or would have to become registrants even
absent this rule in order to handle schedule I hallucinogens). Further,
this rule does not impose any additional regulatory burden on the
regulated community. The change simply will ensure that consistent
criteria are utilized in making scheduling determinations.
Executive Order 12866
The Deputy Administrator further certifies that this rulemaking has
been drafted in accordance with the principles in Executive Order 12866
Sec. 1(b). It has been determined that this is a significant
regulatory action. Therefore, this action has been reviewed by the
Office of Management and Budget.
Executive Order 12988
This regulation meets the applicable standards set forth in
Sec. Sec. 3(a) and 3(b)(2) of Executive Order 12988 Civil Justice
Reform.
Executive Order 13132
This rulemaking does not preempt or modify any provision of state
law; nor does it impose enforcement responsibilities on any state; nor
does it diminish the power of any state to enforce its own laws.
Accordingly, this rulemaking does not have federalism implications
warranting the application of Executive Order 13132.
Unfunded Mandates Reform Act of 1995
This rule will not result in the expenditure by State, local, and
tribal governments, in the aggregate, or by the private sector, of
$120,000,000 or more (adjusted for inflation) in any one year, and will
not significantly or uniquely affect small governments. Therefore, no
actions were deemed necessary under the provisions of the Unfunded
Mandates Reform Act of 1995.
Congressional Review Act
This rule is not a major rule as defined by section 804 of the
Small Business Regulatory Enforcement Fairness Act of 1996
(Congressional Review Act). This rule will not result in an annual
effect on the economy of $114,000,000 or more; a major increase in
costs or prices; or significant adverse effects on competition,
employment, investment, productivity, innovation, or on the ability of
United States-based companies to compete with foreign-based companies
in domestic and export markets.
List of Subjects in 21 CFR Part 1300
Controlled substances, Definitions, Drug Traffic Control.
0
For the reasons set out above, 21 CFR part 1300 is amended as follows:
PART 1300--DEFINITIONS [AMENDED]
0
1. The authority citation for Part 1300 continues to read as follows:
Authority: 21 U.S.C. 802, 871(b), 951, 958(f).
0
2. Section 1300.01 is amended by revising paragraph (b)(21) to read as
follows:
Sec. 1300.01 Definitions relating to controlled substances.
* * * * *
(b) * * *
(21) (i) The term isomer means the optical isomer, except as used
in Sec. 1308.11(d) and Sec. 1308.12(b)(4) of this chapter. As used in
Sec. 1308.11(d) of this chapter, the term ``isomer'' means any
optical, positional, or geometric isomer. As used in Sec.
1308.12(b)(4) of this chapter, the term ``isomer'' means any optical or
geometric isomer.
(ii) As used in Sec. 1308.11(d) of this chapter, the term
``positional isomer'' means any substance possessing the same molecular
formula and core structure and having the same functional group(s) and/
or substituent(s) as those found in the respective schedule I
hallucinogen, attached at any position(s) on the core structure, but in
such manner that no new chemical functionalities are created and no
existing chemical functionalities are destroyed relative to the
respective schedule I hallucinogen. Rearrangements of alkyl moieties
within or between functional group(s) or substituent(s), or divisions
or combinations of alkyl moieties, that do not create new chemical
functionalities or destroy existing chemical functionalities, are
allowed i.e., result in compounds which are positional isomers. For
purposes of this definition, the ``core structure'' is the parent
molecule that is the common basis for the class; for example,
tryptamine, phenethylamine, or ergoline. Examples of rearrangements
resulting in creation and/or destruction of chemical functionalities
(and therefore resulting in compounds which are not positional isomers)
include, but are not limited to: ethoxy to alpha-hydroxyethyl, hydroxy
and methyl to methoxy, or the repositioning of a phenolic or alcoholic
hydroxy group to create a hydroxyamine. Examples of rearrangements
resulting in compounds which would be positional isomers include: tert-
butyl to sec-butyl, methoxy and ethyl to isopropoxy, N,N-diethyl to N-
methyl-N-propyl, or alpha-methylamino to N-methylamino.
* * * * *
Dated: November 21, 2007.
Michele M. Leonhart,
Deputy Administrator,
[FR Doc. E7-23413 Filed 11-30-07; 8:45 am]
BILLING CODE 4410-09-P